Arm 1: Routine Care (Mupirocin/CHG) vs Arm 2: Iodophor/CHG Decolonization: Number of Participants With ICU-attributable Bloodstream Infections
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0105 | 0.01 | 0.011 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0106 | 0.0101 | 0.011 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0000786 | -0.000752 | 0.000597 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.993 | 0.931 | 1.06 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.992 | 0.93 | 1.06 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Arm 1: Routine Care (Mupirocin/CHG) than on Arm 2: Iodophor/CHG Decolonization | 12,700 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Arm 1: Routine Care (Mupirocin/CHG) | ICU nasal decolonization with mupirocin twice daily for 5 days in the context of chlorhexidine for daily bathing~Arm 1. Routine Care (Mupirocin/CHG): The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths. | 1,766 | 168,301 | OG000 | ClinicalTrials.gov |
| Group 2 | Arm 2: Iodophor/CHG Decolonization | ICU nasal decolonization with iodophor twice daily for 5 days in the context of chlorhexidine for daily bathing~Arm 2. Iodophor/CHG Decolonization: The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths. | 1,956 | 185,022 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Number of Participants With ICU-attributable Bloodstream Infections | ClinicalTrials.gov |
| Description | All-cause bloodstream infection attributable to participating ICUs. Defined as occurring \>2 days into a participating ICU stay through 2 days following ICU discharge.Includes subsets of gram positive (GP), gram negative (GN) and fungal (candida) bloodstream infections, as well as key pathogens such as S. aureus (MRSA and MSSA). NOTE: this outcome is intended for the primary manuscript. | ClinicalTrials.gov |
| Time frame | 18-month intervention | ClinicalTrials.gov |
| Population | The total number of participants analyzed reported here is from the intervention period. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Mupirocin-Iodophor ICU Decolonization Swap Out Trial | ClinicalTrials.gov |
| NCT number | NCT03140423 | ClinicalTrials.gov |
| Phases | PHASE4 | ClinicalTrials.gov |
| Conditions | Staphylococcus Aureus | ClinicalTrials.gov |
| Interventions | Arm 1. Routine Care (Mupirocin/CHG), Arm 2. Iodophor/CHG Decolonization | ClinicalTrials.gov |
| Lead sponsor | Harvard Pilgrim Health Care | ClinicalTrials.gov |
| Results first posted | 2024-02-07 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03140423?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.